November 18, 2026
Health news, explained with evidence
LIVE
Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine The Role of Daily Mobility Training in Managing Sedentary Tension New Theoretical Framework Explores Memory Formation and Dementia Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine The Role of Daily Mobility Training in Managing Sedentary Tension New Theoretical Framework Explores Memory Formation and Dementia

U.S. Biotechnology Firms Shift Strategy Amid Rising Competition From China

🏥 Public Health 2 min read 👁 3

American biotechnology companies are increasingly withholding early-stage research and delaying disclosures to protect their intellectual property from competitors in China.

U.S. Biotechnology Firms Shift Strategy Amid Rising Competition From China🏥Public Health

Photo: The New York Times Health

Key points

  • U.S. biotech companies are restricting early-stage research disclosures to protect intellectual property.
  • Data shows China's share of early-stage drug development grew from 8 percent in 2015 to 32 percent in 2024.
  • Advisory groups warn that shifting global drug development shares could impact future economic and medical security.

A growing number of U.S. biotechnology startups and executives are adopting a guarded approach to scientific research, choosing to keep early-stage findings and unpublished data under wraps. According to industry leaders, traditional practices such as presenting posters at academic meetings, discussing discoveries on company websites, and publishing preprints are increasingly seen as too risky. Executives like Dr. Christoph Westphal of Alnylam Pharmaceuticals, Jacob Becraft of Strand Therapeutics, and investor Alexis Borisy note that firms are opting to delay patent filings and restrict attendance at scientific conferences.

This defensive posture is largely driven by concerns that Chinese companies, aided by heavy state subsidies and artificial intelligence tools that scan academic meetings and filings, will quickly replicate or accelerate new discoveries to market. Industry analysts point to a significant shift in global drug development: data from a recent paper published in JAMA highlights that early-stage drug development in the U.S. dropped from 48 percent in 2015 to 37 percent in 2024, while China's share grew from 8 percent to 32 percent over the same timeframe.

Advisory groups, including the National Security Commission on Emerging Biotechnology, have also raised broader strategic concerns in reports to Congress. Experts warn that losing market exclusivity could create economic vulnerabilities and potential geopolitical leverage regarding future drug access, such as cancer treatments. Although Chinese firms often benefit from faster clinical trial timelines and substantial governmental support, U.S. advocates argue that American companies continue to face funding hurdles tied to venture capital cycles.

What to know: U.S. biotech firms are altering long-standing standards of academic openness to safeguard innovations against rapid global competition. For personal health decisions and questions regarding specific medical treatments, patients should always consult a qualified healthcare provider.

Source The New York Times Health — nytimes.com/2026/11/17/science/fearing-chinese-rivals-us-biotech-ad… ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.